Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia | Zendy

Melanie D. Whittington | Zendy; R. Brett McQueen | Zendy; Daniel A. Ollendorf | Zendy; Varun Kumar | Zendy; Richard H. Chapman | Zendy; Jeffrey A. Tice | Zendy; Steven D. Pearson | Zendy; Jonathan D. Campbell | Zendy

Open Access

Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia

Author(s) -

Melanie D. Whittington,

R. Brett McQueen,

Daniel A. Ollendorf,

Varun Kumar,

Richard H. Chapman,

Jeffrey A. Tice,

Steven D. Pearson,

Jonathan D. Campbell

Publication year - 2018

Publication title -

jama pediatrics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.004

H-Index - 183

eISSN - 2168-6211

pISSN - 2168-6203

DOI - 10.1001/jamapediatrics.2018.2530

Subject(s) - medicine , survival analysis , chimeric antigen receptor , oncology , refractory (planetary science) , pediatrics , immunotherapy , cancer , physics , astrobiology

Among children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia, the rate of 5-year disease-free survival is 10% to 20%. Approval of tisagenlecleucel, a chimeric antigen receptor T-cell therapy, represents a new and potentially curative treatment option. However, tisagenlecleucel is expensive, with a current list price of $475 000 per one-time administration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research